Insight into the interplay between mitochondria-regulated cell death and energetic metabolism in osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metabolism

Background:

• Osteosarcoma (OS) is a pediatric bone cancer with poor prognosis and high relapse rates.
• Current treatments for OS have not improved patient outcomes in decades.
• Mitochondria-related regulated cell death (RCD) and metabolic reprogramming are key cancer hallmarks dysregulated in OS.

Purpose of the Study:

• To review the interplay between regulated cell death (RCD) and metabolism in osteosarcoma (OS).
• To synthesize current knowledge on various RCD types (apoptosis, ferroptosis, necroptosis, pyroptosis, autophagy) in OS.
• To discuss novel therapeutic strategies targeting these pathways.

Main Methods:

• Systematic review of existing literature on RCD and metabolism in OS.
• Analysis of mitochondrial function and metabolic profiles in preclinical OS models.
• Discussion of emerging drug combinations in clinical trials.

Main Results:

• Dysregulation of RCD and metabolism are critical in OS development and progression.
• Targeting metabolic reprogramming offers potential for promoting RCD in OS.
• Novel drug combinations show promise in ongoing clinical investigations.

Conclusions:

• Understanding the intricate link between RCD and metabolism is crucial for developing effective OS therapies.
• Novel therapeutic strategies targeting these pathways may overcome drug resistance and reduce metastasis in OS.
• Further research into metformin and combination therapies (ADI-PEG20, Docetaxel, Gemcitabine) is warranted.